Rittberg, R.; Harlos, C.; Rothenmund, H.; Das, A.; Tabori, U.; Sinha, N.; Singh, H.; Chodirker, B.; Kim, C.A.
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD. Curr. Oncol. 2021, 28, 757-766.
https://doi.org/10.3390/curroncol28010074
AMA Style
Rittberg R, Harlos C, Rothenmund H, Das A, Tabori U, Sinha N, Singh H, Chodirker B, Kim CA.
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD. Current Oncology. 2021; 28(1):757-766.
https://doi.org/10.3390/curroncol28010074
Chicago/Turabian Style
Rittberg, Rebekah, Craig Harlos, Heidi Rothenmund, Anirban Das, Uri Tabori, Namita Sinha, Harminder Singh, Bernie Chodirker, and Christina A. Kim.
2021. "Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD" Current Oncology 28, no. 1: 757-766.
https://doi.org/10.3390/curroncol28010074
APA Style
Rittberg, R., Harlos, C., Rothenmund, H., Das, A., Tabori, U., Sinha, N., Singh, H., Chodirker, B., & Kim, C. A.
(2021). Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD. Current Oncology, 28(1), 757-766.
https://doi.org/10.3390/curroncol28010074
